Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 May;76(5):795-800.

Spectrum of Rift Valley fever virus transmission in Kenya: insights from three distinct regions

A Desiree LaBeaud  1 , Yoshitsugu Ochiai, C J Peters, Eric M Muchiri, Charles H King
Affiliations

Spectrum of Rift Valley fever virus transmission in Kenya: insights from three distinct regions

A Desiree LaBeaud et al. Am J Trop Med Hyg. 2007 May.

Abstract

Rift Valley fever virus (RVFV) is an emerging pathogen that maintains high biodefense priority based on its threat to livestock, its ability to cause human hemorrhagic fever, and its potential for aerosol spread. To define the range of human transmission during inter-epidemic and epidemic periods in Kenya, we tested archived sera from defined populations (N = 1,263) for anti-RVFV IgG by ELISA and plaque reduction neutralization testing. RVFV seroprevalence was 10.8% overall and varied significantly by location, sex, and age. In NW Kenya, high seroprevalence among those born before 1980 indicates that an undetected epidemic may have occurred then. Seroconversion documented in highland areas suggests previously unsuspected inter-epidemic transmission. RVFV seroprevalence is strikingly high in certain Kenyan areas, suggesting endemic transmission patterns that may preclude accurate estimation of regional acute outbreak incidence. The extent of both epidemic and inter-epidemic RVFV transmission in Kenya is greater than previously documented.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Locations and seroprevalence of RVF study sites in Kenya.
Figure 2
Figure 2
Lokichoggio RVF seropositivity by age group (N = 675) with 95% confidence intervals.
See this image and copyright information in PMC

References

    1. CDC. Viral hemorrhagic fevers: fact sheets. 2002. Rift Valley fever; pp. 1–3.
    1. Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis. 2001;33:1707–1712. - PubMed
    1. WHO. WHO Fact Sheet No 207. 2000. Rift Valley fever; pp. 1–5.
    1. Laughlin LW, Meegan JM, Strausbaugh LJ. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg. 1979;73:630–633. - PubMed
    1. Peters CJ. The role of antivirals in responding to biological threats. In: Knobler SL, Mahmoud AAF, Pray LA, editors. Biological Threats and Terrorism: Assessing the Science and Response Capabilities. Washington: National Academy Press; 2002. pp. 119–130. - PubMed

Publication types

Substances